COMMUNIQUÉS West-GlobeNewswire
-
IvesMD Opens New Beverly Hills Headquarters, Expands Team to Meet Growing Demand for Inclusive Aesthetic and Gender-Affirming Care
30/12/2025 -
Best Weight Loss Pills for 2026? FDA Approves First Oral GLP-1 as Patients Evaluate Wegovy, Zepbound, and Telehealth Access Pathways
30/12/2025 -
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
30/12/2025 -
Changes in company's own shares
29/12/2025 -
CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®
29/12/2025 -
Nyxoah Fera une Présentation lors de la 44ème Conférence Annuelle J.P. Morgan Healthcare
29/12/2025 -
Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference
29/12/2025 -
CooperCompanies to Present at the J.P. Morgan Healthcare Conference
29/12/2025 -
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
29/12/2025 -
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
29/12/2025 -
Genmab Portfolio Prioritization Update
29/12/2025 -
MEDIROM Partners with World on Technology Envisioned by Sam Altman and Alex Blania: Deploying “Proof of Human” Infrastructure throughout Japan
29/12/2025 -
The Better Brain Company’s Dementia Prevention Expert Dr. Clint Steele Releases “101 Brain Hacks To Prevent and Even Reverse Dementia”
29/12/2025 -
Branded Legacy, Inc. Announces Successful Retirement of Legacy Convertible Debt as New Management Focuses on Balance Sheet Optimization and OTC Yield Sign Removal
29/12/2025 -
QHSLab, Inc. (OTCQB:USAQ) Completes $500K Private Placement, Enters 2026 With Clean Capital Structure
29/12/2025 -
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
29/12/2025 -
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
29/12/2025 -
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
29/12/2025 -
WORK Medical Technology Group LTD Subsidiary Obtains Manufacturing Approval for Its AI-Automated Blood Cell Morphology Analyzer
29/12/2025
Pages